NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University Jul 28, 2022 10:38AM
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabil Jan 10, 2022 07:30AM
NervGen Pharma To Webcast At VirtualInvestorConferences.com July 11th Jul 9, 2019 10:52AM